and a five-year overall survival ranging from 18 to 46 percent. Most patients die because of extensive peritoneal disease burden and malignant bowel obstruction.
"Due to the explosion of immune and targeted therapies in the past few decades—particularly those targeting HER2—there is increasing interest in the potential role of alternative, more innovative therapies to cure ," said Sarah M. Cheal, Ph.D., of the Molecular Imaging Innovations Institute in the Department of Radiology at Weill Cornell Medical College in New York, New York.and explored whether this could effectively treat the disease without significant toxicity."included five groups of eight to 10 nude mice, each bearing peritoneal carcinomatosis tumors.
Tumors spread rapidly in untreated mice, leading to a median survival of approximately four months. When treated with one or two cycles of anti-HER2Ac-PRIT, however, median survival was not reached after 154 days. At the end of the study, 75 percent of mice in the anti-HER2